» Articles » PMID: 3500218

Synergistic and Antagonistic Effects of Recombinant Human Interleukin (IL) 3, IL-1 Alpha, Granulocyte and Macrophage Colony-stimulating Factors (G-CSF and M-CSF) on the Growth of GM-CSF-dependent Leukemic Cell Lines

Overview
Journal J Immunol
Date 1987 Nov 15
PMID 3500218
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Three human leukemia cell lines (TALL-101, AML-193, and MV4-11) that require granulocyte/macrophage-colony stimulating factor (GM-CSF) for growth in a chemically defined medium were examined for their response to recombinant human (rh) cytokines. Either rh interleukin (IL)-3 or rhGM-CSF alone supported the long term growth of all three cell lines, and the two growth factors acted synergistically to stimulate the proliferation of the early T lymphoblastic leukemia (TALL-101) and of the monocytic leukemia (AML-193) cells. However, IL-3 antagonized the proliferation of the biphenotypic B-myelomonocytic leukemia (MV4-11) cells in the presence of GM-CSF when both factors were used at very low concentrations. The rh granulocyte (G)-CSF independently supported the long and short term growth of AML-193 and MV4-11, respectively, and synergized with GM-CSF in inducing proliferation of these cells. By contrast, G-CSF did not stimulate TALL-101 cell growth and antagonized the effect of GM-CSF such that proliferation was arrested. Although neither rh macrophage (M)-CSF nor rhIL-1 alpha independently promoted proliferation of the three leukemia cell lines, these cytokines were able to either up- or down-regulate the GM-CSF-dependent growth of these cells. Taken together, these data demonstrate that leukemic cells often require the synergistic action of several cytokines for optimal growth, whereas other combinations of factors may be growth-inhibitory. This raises the possibility that multiple hemopoietic growth factors sustain or control leukemic cell proliferation also in vivo. In addition, the observation the G-CSF, M-CSF, and IL-1 alpha can, in some cases, arrest cell proliferation without inducing differentiation suggests that the programs of proliferative arrest and differentiation in leukemic cells can be dissociated.

Citing Articles

The cytokine network in acute myeloid leukemia.

Luciano M, Krenn P, Horejs-Hoeck J Front Immunol. 2022; 13:1000996.

PMID: 36248849 PMC: 9554002. DOI: 10.3389/fimmu.2022.1000996.


Loss of SIRT1 inhibits hematopoietic stem cell aging and age-dependent mixed phenotype acute leukemia.

Wang Z, Zhang C, Warden C, Liu Z, Yuan Y, Guo C Commun Biol. 2022; 5(1):396.

PMID: 35484199 PMC: 9051098. DOI: 10.1038/s42003-022-03340-w.


Development of Murine Leukemia Virus Integrase-Derived Peptides That Bind Brd4 Extra-Terminal Domain as Candidates for Suppression of Acute Myeloid Leukemia.

Xing E, Surendranathan N, Kong X, Cyberski N, Garcia J, Cheng X ACS Pharmacol Transl Sci. 2021; 4(5):1628-1638.

PMID: 34661079 PMC: 8506603. DOI: 10.1021/acsptsci.1c00159.


A compound combination screening approach with potential to identify new treatment options for paediatric acute myeloid leukaemia.

Lappin K, Davis L, Matchett K, Ge Y, Mills K, Blayney J Sci Rep. 2020; 10(1):18514.

PMID: 33116257 PMC: 7595190. DOI: 10.1038/s41598-020-75453-3.


A novel tetrazole analogue of resveratrol is a potent anticancer agent.

Bommagani S, Penthala N, Balasubramaniam M, Kuravi S, Caldas-Lopes E, Guzman M Bioorg Med Chem Lett. 2018; 29(2):172-178.

PMID: 30528695 PMC: 6497071. DOI: 10.1016/j.bmcl.2018.12.006.